Kare Schultz - Feb 28, 2022 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: President and CEO, Director
Signature: /s/ Dov Bergwerk as attorney-in-fact for Kare Schultz
Stock symbol: TEVA
Transactions as of: Feb 28, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/2/2022, 06:51 AM
Previous filing: Feb 10, 2022
Next filing: Mar 8, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+65K	+6.09%		1.13M	Feb 28, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise	$0	-65K	-33.33%	$0.00	130K	Feb 28, 2022	Ordinary Shares	65K		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	Restricted share units were granted on February 28, 2020, with 65,047 having vested on each of February 28, 2021 and February 28, 2022, 65,047 vesting on February 28, 2023 and 65,049 vesting on February 28, 2024.